Fluorescent In Situ Hybridization Probe Market Size, Share, Growth, and Industry Analysis, By Type (mRNA and miRNA), By Application (Research, Clinical and Companion Diagnostics), and Regional Insights and Forecast to 2034

•   
•   
  

  Request a Free sample to learn more about this report

    

FLUORESCENT IN SITU HYBRIDIZATION PROBE MARKET OVERVIEW

The global fluorescent in situ hybridization probe market size was USD 0.19 billion in 2025 and is projected to touch USD 0.28 billion by 2034, exhibiting a CAGR of 4.3% during the forecast period.

Increasing genetic diseases, cancer and infectious diseases such as tuberculosis (TB) and AIDS will push the fluorescent in situ hybridization probe market growth in coming years. FISH probes are the widely used reagent for clinical molecular diagnosis to acquire detail information of chromosome abnormalities and gene mutations in high sensitivity and specificity. Growing demand for personalized and or targeted therapies, together with expanding applications for FISH probes have also contributed to a growing adoption of these tests as they are fundamental in identifying biomarkers used in disease risk factor assays, and development. Furthermore, increasing use of FISH to gene mapping and microbial identification research-based applications will serve to boost the industry growth. The technological advancement in probe design and labelling paired with laboratory process automation are also enhancing accuracy and throughput, thereby establishing FISH as an attractive technique worldwide in clinical and research laboratories.

In addition, the market is supported by rising investment in genomics research and growing tie-ups with diagnostic companies and hospitals. Research programs on the improvement of precision diagnostics are being supported by public and private sector defaulting in an acceleration for routine clinical use of FISH probes. Growing awareness of early disease detection and introduction of advanced molecular testing is creating demand in developed markets such as North America and Europe. The same holds true for most of the emerging economies in Asia-Pacific which are witnessing a high rate of adoption due to growing health infrastructure and awareness among patients. However, in some areas high test costs and a requirement of skilled personnel are still barriers. In spite of these challenges, the market is expected to remain optimistic owing to efforts being made by manufacturers in formulating novel probes that will be both cost-effective and multiplexed. With a growing emphasis on personalising medicine and early diagnosis from healthcare systems, the FISH probe market will continue to expand.

COVID-19 IMPACT

Fluorescent In Situ Hybridization Probe Industry Had a Positive Effect Due to urgent need for accurate and rapid diagnostic testing during COVID-19 Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

Impact of COVID-19 pandemic has cast a huge impact on the fluorescent in situ hybridization (FISH) probe since there was urgent requirement for rapid and accurate diagnostic testing. Molecular diagnostics, a main approach to detecting viral infections, had seen a flood of orders from labs around the world looking for probes that could be used in research and diagnosis. FISH was considered as a kind of high-specificity genetic level molecular detection technology and it was widely used for the understanding of virus mutant strains, patient outcome monitoring and vaccine development.  At the same time, pandemic-induced supply chain interruptions for reagents and lab materials produced immediate complications for manufacturers and laboratories. The overall impact was moderate, but it seems beneficial in the long run as there was an increase to investments in cutting edge molecular diagnostics which will contribute to being outbreak-ready. Rampant investments being made in genomic research and infectious disease studies also stimulated market growth. COVID-19 brought into sharp focus the urgent need for FISH probes in clinical testing, driving awareness and adoption of our products and positioning us well for continued growth beyond the pandemic.

LATEST TRENDS

Multiplexing and Automation in FISH Probes to Drive Market Growth

One of latest trends in the FISH probe market is demand for multiplexed & automated solutions. The multicolour FISH probes permit the parallel imaging of multiple genetic targets in a single assay to increase throughput and expedite time to reportable results for diagnostic or research use. The driver is the growing demand for personal medicine and targeted therapy where a precise genetic mutation or chromosomal abnormalities needs to be identified. Automation is also increasing, and many laboratories are using robotic systems and software for slide staining, tissue or data file imaging for image analysis, and data mining. This reduces risk of human error, enhances repeatability and throughput for high-capacity clinical and research laboratories. Moreover, sensitive and stable fluorescent probe that is compatible with high-resolution imaging technology is being developed. These could be used, for example in oncology, prenatal diagnostics and infectious disease. In general, FISH probes are increasingly becoming subject to multiplexing and automated processes which increase accuracy, efficiency, and worldwide usage of the technology.

•   
•   
  

  Request a Free sample to learn more about this report

    

FLUORESCENT IN SITU HYBRIDIZATION PROBE MARKET SEGMENTATION

By Type

Based on type, the global market can be categorized into mRNA and miRNA

• mRNA: mRNA FISH probes are commonly used to visualize and measure the expression of messenger RNA in cells and tissues. They are essential tool to investigate gene function and cellular processes. The high sensitivity and specificity of mRNA probes, render conventional eukaryote mRNA probes indispensable in research as well as clinical applications.

• miRNA: miRNA FISH probes vis designed to identify the microRNAs that control gene expression, and are associated with a wide variety of diseases. These probes are used more and more widely in cancer research and biomarker discovery. Their sensitivity to subtle expression changes makes them valuable for precision medicine and targeted therapies.

By Application

Based on application, the global market can be categorized into research, clinical and companion diagnostics

• Research: Applications in research FISH probe applications for studying gene expression, chromosomal abnormalities, and molecular mechanisms. Both academic and pharmaceutical labs use FISH for experimental reproducibility and high resolution im- aging. It allows researchers to investigate new sources and confirm hypotheses in molecular biology.

• Clinical: For clinical uses, it is used to diagnose genetic disorders, cancers and infectious diseases. Rapid, robust and accurate FISH analysis supports the patient management and monitoring. FISH has become rapidly adopted in both hospitals and diagnostic laboratories as a routine test for its reliable and accurate reporting.

• Companion Diagnostics: FISH probes are used in companion diagnostics to determine the eligibility of patients for targeted therapies. These are particularly important in oncology for choosing treatments according to particular genetic markers. Adoption is increasing as personalized medicine scales worldwide.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

Rising Prevalence of Genetic Disorders and Cancer to Boost the Market

Growing incidences of genetic disorders, cancer, and chromosomal anomalies are a key driver for the fluorescent in situ hybridization probe market growth. FISH allows the detection of targeted DNA and RNA sequences, making it an ideal diagnostic assay for referral laboratories and other clinical facilities as well as in research. The increasing prevalence of diseases like leukaemia, breast cancer and lung cancers has further boosted the demand for FISH probes for expedited processes used in determining gene amplifications and chromosomal translocations, to both diagnose at an early stage as well as plan treatment. The growth in prenatal and paediatric testing for genetic abnormalities is also adding to the demand for precise molecular diagnostics. FISH is increasingly utilized in drug development and biomarker discovery by research centres and pharmaceuticals. The FISH tests have been incorporated into sophisticated imaging instruments and automated platforms to provide high throughput, reproducibility and accuracy, and can support testing in large scales. As a result, increasing prevalence of diseases and the importance of FISH in diagnosis is driving the growth of global market.

Expansion of Personalized Medicine and Targeted Therapies to Expand the Market

Market development of FISH probe is largely driven by a movement toward personalized medicine and targeted therapies. Genetic profiling plays an increasing role in selecting treatment and determining the right patient populations to target with particular therapies for healthcare providers as well as drug makers. FISH probes are essential for companion diagnostics, which is especially relevant when it comes to oncology and the detection of biomarkers such as HER2 amplification or ALK translocations required for therapy. The development of multiplex FISH probes and automated imaging is making diagnosis even more efficient and integrated into the clinical workflow. Moreover, regulatory backing and increasing awareness regarding precision medicine have driven hospitals and clinics and labs toward FISH testing for routine patient care. Growing genomic investment and development of new therapies is also broadening the applications of FISH probes. Together these support the FISH instrumental role to facilitate personalized medicine and contribute to ongoing demand in research, clinical and diagnostic applications worldwide.

Restraining Factor

High Costs and Technical Complexity to Potentially Impede Market Growth

High cost of probes, reagents, and other instruments in laboratories is one of the major factors limiting growth of FISH probe market. The overall cost for FISH testing, from slide preparation to fluorescence labelling and imaging, can be too expensive, especially for smaller labs or clinics in developing areas. Moreover, the method demands specific expertise and it is necessary to be trained to infer data interpretation, hindering its broad use. Mistakes in probe design, hybridization or imaging can contribute to false findings, and consequently dissatisfaction with diagnostic use. Costs are also increased by the requirements for controlled laboratory conditions and sophisticated imaging equipment. Furthermore, other molecular assays, including PCR and next generation sequencing (NGS), possibly provide faster or more economical solutions that induce a competitive pressure. Collection of high cost, technical difficulty and competition with other diagnosis measure limits the applications of FISH probe, especially in some undeveloped areas, although it had extremely specificity and clinical value.

Growth in Personalized Medicine and Research Applications To Create Opportunity for the Product in the Market

Opportunity

The increasing popularity of personalized medications and targeted therapeutics translates into a major opportunity for the FISH probe market. References have been Established FISH probes are being used extensively as a companion diagnostic to guide individualised selection of patients for targeted therapy and improved clinical outcomes especially in cancer. The increasing emphasis of pharmaceutical companies and health care professionals in precision medicine is broadening the need for high quality probes to detect specific genetic markers.

Further technical developments in multiplex FISH methodology, automation and high-resolution imaging solutions are promoting faster, accurate and high throughput testing in clinical and research applications. Research uses, including gene mapping, chromosomal analysis and microbial identification, still are expanding as scientists look for better tools to figure out what ills us as well as help in developing new drugs. What’s more, growing recognition of early detection and preventive healthcare is prompting to the adoption FISH testing in the standard test routine that provide extended growth opportunity for market participants.

Regulatory Complexity and Limited Skilled Workforce Could Be a Potential Challenge for Consumers

Challenge

One of the major challenges faced by FISH probe market is the stringent government regulations in molecular diagnostics. It can be time consuming and expensive to gain an approval from agencies like FDA, EMA or other regional authorities, particularly for new probes and multiplex assays. Quality and safety standards are high, so delays in getting approval can stall market entry or result in less-robust market growth. It also demands extensive training for personnel to administer and interpret tests correctly.

The shortage of trained laboratory personnel, especially in developing countries is a hinderance for FISH technology because although it has a superior clinical use potential, the adoption may be difficult. These errors can detract from the results, and ultimately have a deleterious impact on diagnostic confidence and patient outcome. There is also increasing competition from other PCR molecular testing technologies such as microarrays, and NGS in some cases that are sometimes faster or less costly. Both, regulatory bottleneck and shortage of workforce continue to hamper the growth of the global FISH probe market.

•   
•   
  Request a Free sample to learn more about this report

    

FLUORESCENT IN SITU HYBRIDIZATION PROBE MARKET REGIONAL INSIGHTS

• North America

The United States fluorescent in situ hybridization probe market is experiencing strong growth due to advanced healthcare infrastructure and widespread adoption of molecular diagnostic technologies. High prevalence of genetic disorders, cancers, and chronic diseases is driving demand in hospitals, research institutions, and diagnostic laboratories. Government initiatives supporting precision medicine, alongside the increasing use of companion diagnostics, are further boosting market expansion. The presence of leading biotechnology and pharmaceutical companies also supports continuous innovation in probe design, automation, and imaging systems, enhancing the efficiency and accuracy of fluorescent in situ hybridization probe testing. Additionally, increasing investment in genomics research and early disease detection programs is propelling the adoption of fluorescent in situ hybridization probes across clinical and research applications.

• Europe

The European fluorescent in situ hybridization probe market share is expanding steadily, driven by robust healthcare systems and regulatory frameworks encouraging early disease detection. Countries such as Germany, France, and the United Kingdom are leading adoption, with hospitals and research centers increasingly relying on fluorescent in situ hybridization probes for oncology, prenatal diagnostics, and genetic studies. Rising investments in personalized medicine and the integration of multiplexing and high-resolution imaging technologies are further driving market growth. Moreover, government funding for genomics research and growing patient awareness of molecular diagnostics are supporting increased utilization of fluorescent in situ hybridization probes across both clinical and research settings.

• Asia

The Asia fluorescent in situ hybridization probe market is witnessing rapid growth due to expanding healthcare infrastructure and rising awareness of early disease detection. China, India, and Japan are the major contributors, with hospitals and research laboratories increasingly adopting fluorescent in situ hybridization probes for cancer diagnostics and detection of genetic disorders. Growing investments in precision medicine, combined with government initiatives promoting molecular diagnostics, are accelerating market adoption. Additionally, collaborations between local and international biotechnology firms are facilitating the introduction of high-quality probes and advanced technologies in the region, supporting overall growth of the Asia fluorescent in situ hybridization probe market.

KEY INDUSTRY PLAYERS

Key Industry Players Shaping the Market Through Innovation and Market Expansion

Leading players in the fluorescent in situ hybridization probe market are focusing on innovation, strategic collaborations, and geographic expansion to strengthen their market presence. Companies are investing in research and development to create highly sensitive, multiplexed, and automated FISH probes that improve accuracy and reduce testing time in both clinical and research applications. Partnerships with hospitals, diagnostic laboratories, and academic institutions are being established to enhance adoption and provide comprehensive training programs for laboratory professionals. Manufacturers are also expanding production capacities and distribution networks to meet rising demand in emerging markets, particularly in Asia-Pacific. Additionally, efforts are being made to develop cost-effective solutions and eco-friendly reagents to address affordability and sustainability concerns. Marketing campaigns and educational initiatives are increasing awareness about the clinical and research benefits of fluorescent in situ hybridization probes, helping players capture a larger share of the growing molecular diagnostics market.

List Of Top Fluorescent In Situ Hybridization Probe Companies

• Mirus Bio LLC (United States)
• Life Science Technologies (United States)
• PerkinElmer Inc (United States)
• BioDot Inc. (United States)
• Horizon Diagnostics (United Kingdom)
• Sigma-Aldrich Corporation (United States)
• Agilent Technologies (United States)
• Abnova Corporation (Taiwan)
• Biosearch Technologies Inc. (United States)
• Genemed Biotechnologies, Inc. (United States)
• AffymetrixPanomics (United States)
• F. Hoffman-La Roche AG Life Science (Switzerland)
• Oxford Gene Technology (United Kingdom)
• Bio Care Medical, LLC (United States)
• EXIQON (Denmark)
• GSP Research Institute Co., Ltd. (China)

KEY INDUSTRY DEVELOPMENT

March 2024: PerkinElmer Inc (United States) announced the launch of a new line of multiplex fluorescent in situ hybridization probes designed for oncology and genetic research. The new probes allow simultaneous detection of multiple genetic markers, improving diagnostic accuracy and reducing testing time in clinical laboratories. This development supports the growing demand for personalized medicine and companion diagnostics, particularly in cancer treatment. The launch also includes enhanced compatibility with automated imaging systems, enabling high-throughput analysis in both research and clinical settings. By expanding its product portfolio, PerkinElmer aims to strengthen its position in the global fluorescent in situ hybridization probe market and cater to increasing adoption in North America, Europe, and Asia.

REPORT COVERAGE

The report provides a detailed analysis of the global fluorescent in situ hybridization probe market, highlighting key trends, drivers, restraints, opportunities, and challenges shaping industry growth. It covers market segmentation by type, including mRNA and miRNA probes, and by application, such as research, clinical, and companion diagnostics. The study also examines regional insights across North America, Europe, and Asia, providing a comprehensive view of market dynamics, demand patterns, and regulatory influences. Additionally, technological advancements in multiplexing, automation, and high-resolution imaging are discussed, showcasing their impact on market expansion.

The report further evaluates the competitive landscape, profiling major players and their strategic initiatives, including research and development, partnerships, capacity expansion, and product launches. Key industrial developments, such as the launch of new probes for oncology and genetic research, are highlighted to illustrate market trends. By analyzing consumer demand, healthcare infrastructure, and molecular diagnostic adoption, the report offers actionable insights for stakeholders seeking to capitalize on growth opportunities in the fluorescent in situ hybridization probe market.